Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis Xiaodi GuoWendong LiQiang Su Review Open access 08 June 2020 Pages: 1345 - 1354
Patient safety incidents and medication errors during a clinical trial: experience from a pre-hospital randomized controlled trial of emergency medication administration Ed EnglandCharles D. DeakinGavin D. Perkins Clinical Trial 14 June 2020 Pages: 1355 - 1362
Stakeholders’ knowledge, attitudes and practices to pharmacovigilance and adverse drug reaction reporting in clinical trials: a mixed methods study David O. RiordanMary KinaneMargaret Bermingham Clinical Trial 07 June 2020 Pages: 1363 - 1372
Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis Manoj KumarRam BajpaiDivya Vohora Pharmacodynamics 16 June 2020 Pages: 1373 - 1392
Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus Julie DubourgSandrine Perrimond-DauchyPascale Fouqueray Pharmacodynamics 18 June 2020 Pages: 1393 - 1400
ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers Luiz Carlos da Costa JuniorClarissa Lourenço de CastroPaulo Caleb Júnior Lima Santos Pharmacogenetics 20 June 2020 Pages: 1401 - 1408
A decision support tool to find the best cyclosporine dose when switching from intravenous to oral route in pediatric stem cell transplant patients Vincent LeclercNathalie BleyzacMichel Ducher Pharmacokinetics and Disposition 12 June 2020 Pages: 1409 - 1416
Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations Carla BastidaAlwin D.R. HuitemaDolors Soy Pharmacokinetics and Disposition 09 June 2020 Pages: 1417 - 1425
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases Bharati ShriyanDeepali PatilVikram Gota Pharmacokinetics and Disposition 11 June 2020 Pages: 1427 - 1436
The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis Hyun Jin SongNakyung JeonPatrick Squires Pharmacoepidemiology and Prescription 16 June 2020 Pages: 1437 - 1456
Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol Matthijs L. BeckerRenate C.A.E. van UdenPatricia M.L.A. van den Bemt Pharmacoepidemiology and Prescription 10 June 2020 Pages: 1457 - 1464
Accuracy of freely available online GFR calculators using the CKD-EPI equation Sarah SeiberthTheresa TerstegenDavid Czock Pharmacoepidemiology and Prescription Open access 19 June 2020 Pages: 1465 - 1470
Calling for an exponential escalation scheme in vaccine development for COVID-19 Martin Wehling Point of View Open access 16 June 2020 Pages: 1471 - 1472
Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD) I. Agraz-PamplonaM. Larrosa-GarciaJ. B. Montoro-Ronsano Letter to the Editor Open access 08 June 2020 Pages: 1473 - 1475
Professor Folke Sjöqvist peacefully passed away on March 30, 2020 Ylva BöttigerPierre MarquetLars L. Gustafsson Letter to the Editor 10 June 2020 Pages: 1477 - 1478
Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase® Jean-Louis MontastrucVanessa RousseauHaleh Bagheri Letter to the Editor 06 June 2020 Pages: 1479 - 1480
The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro Xia LiRainer HöhlUwe Fuhr Letter to the Editor Open access 18 June 2020 Pages: 1481 - 1482